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Summary objectives To estimate the incremental costs of visual inspection with acetic acid (VIA) and
cryotherapy at cervical cancer screening facilities in Ghana; to explore determinants of costs through
modelling; and to estimate national scale-up and annual programme costs.
methods Resource-use data were collected at four out of six active VIA screening centres, and unit
costs were ascertained to estimate the costs per woman of VIA and cryotherapy. Modelling and sensi-
tivity analysis were used to explore the influence of observed differences between screening facilities on
estimated costs and to calculate national costs.
results Incremental economic costs per woman screened with VIA ranged from 4.93 US$ to
14.75 US$, and costs of cryotherapy were between 47.26 US$ and 84.48 US$ at surveyed facilities.
Under base case assumptions, our model estimated the costs of VIA to be 6.12 US$ per woman and those
of cryotherapy to be 27.96 US$. Sensitivity analysis showed that the number of women screened per
provider and treated per facility was the most important determinants of costs. National annual pro-
gramme costs were estimated to be between 0.6 and 4.0 million US$ depending on assumed coverage
and adopted screening strategy.
conclusion When choosing between different cervical cancer prevention strategies, the feasibility of
increasing uptake to achieve economies of scale should be a major concern.
keywords economics, costs and cost analysis, uterine cervical neoplasms, Africa, early detection
of cancer
Introduction
Cervical cancer is the second most frequent cancer in
women worldwide and is responsible for an estimated
493 000 cases and 274 000 deaths annually (Parkin et al.
2005). More than 80% of cervical cancers occur in
developing countries (Parkin & Bray 2006), and in
Ghana, as in sub-Saharan Africa more generally, cervical
cancer is the leading cause of female cancer deaths
(Shibuya et al. 2002; Parkin et al. 2005; WHO ⁄ ICO
2007). Human papillomaviruses (HPV) are the aetiolog-
ical agents of cervical cancers (Walboomers et al. 1999),
and vaccines against HPV are promising for future
primary prevention of the disease (Goldie et al. 2008;
Bonanni et al. 2009). However, currently, vaccination is
beyond the financial reach of many developing countries,
and therefore, improving screening coverage remains
central to achieving reductions in female cancer mortality
in the short term.
In developing countries, logistical barriers in imple-
menting screening programmes using cytology on Papani-
colaou-stained cervical smears to detect precursor cervical
lesions have led to failures in reducing cervical cancer
incidence and mortality (Denny et al. 2006; Gakidou et al.
2008). Alternative strategies based on visual inspection of
the cervix with acetic acid (VIA) or Lugol’s Iodine (VILI)
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increase the feasibility of screening in resource-poor
settings (Sankaranarayanan et al. 2005; FIGO 2009).
These strategies require little laboratory infrastructure and
provide immediate or very rapid results, allowing treat-
ment with cryotherapy where required in the same visit
(Denny et al. 2005).
The performance of VIA in routine practice has been
assessed in a series of large-scale studies (Sankaranaraya-
nan et al. 2004; Sangwa-Lugoma et al. 2006; Cuzick
et al. 2008), and reductions in cancer mortality have been
observed in a large Indian screening trial linking VIA with
cryotherapy in a single-visit approach (Sankaranarayanan
et al. 2007). Today, VIA followed by immediate cryo-
therapy for all eligible women is one of the internationally
recommended screening strategies for developing
countries (FIGO 2009; Sherris et al. 2009), even though
new low-cost rapid HPV DNA detection tests (e.g.
CareHPV) that have shown higher sensitivity and
specificity than VIA (Qiao et al. 2008) are about to
become available.
In Ghana, where the lifetime risk for women of
developing cervical cancer is about 2.2%, and where
2000 women are estimated to develop cervical cancer
every year (WHO ⁄ ICO 2007), VIA was introduced in
several pilot sites in 2001 (Blumenthal et al. 2007;
JHPIEGO 2008; Sanghvi et al. 2008). Subsequently, the
feasibility, safety and acceptability of VIA combined with
cryotherapy for treatment of precancerous lesions in
Ghana was confirmed (Blumenthal et al. 2007), and plans
for scale-up of a national VIA-based screening pro-
gramme were developed (Odoi-Agyarko 2003). While
lack of a strong political will and competing health
priorities may have prevented the programme from being
implemented (Sanghvi et al. 2008), a new project
organized around Kintampo rural health training centre
has recently trained providers in an attempt to scale-up
VIA screening in rural areas.
International studies have shown VIA combined with
cryotherapy to be more cost-effective than traditional
cytology-based screening strategies (Goldie et al. 2001,
2005; Mandelblatt et al. 2002; Legood et al. 2005).
However, these studies did not base their calculations on
directly observed costs, but relied on fee schedules or a
series of assumptions and expert opinions, except for the
study by Legood et al. (2005) which collected data during
a large screening trial in India. Yet, to plan for scale-up of
screening programmes and to estimate cost-effectiveness of
VIA combined with cryotherapy, policy-makers and
researchers need reliable estimates based on local costs.
This study was conducted in July and August 2009 to
obtain information on the costs of VIA and cryotherapy in
an African setting. Specifically, it aimed to (i) estimate the
costs of screening using VIA and treatment with cryother-
apy at existing screening facilities in Ghana; (ii) explore the
most important determinants of costs through modelling
and (iii) estimate national scale-up and annual programme
costs under varying assumptions for the level of coverage
and the frequency of screening.
Methods
Cost analysis of VIA and cryotherapy at screening facilities
in Ghana
Incremental economic costs of VIA and cryotherapy were
estimated in two steps using an ingredients approach: (i)
quantities of resources used were measured, and (ii) unit
costs or prices were assigned to resources consumed
(Drummond et al. 2005). The analysis adopted a provider
perspective, including only costs of delivering the service
while excluding costs incurred by private households or
administrative costs at higher levels of the health system
(Creese & Parker 1994). As VIA usually constitutes only a
small part of activities at existing facilities, we assumed
that no additional administrative overheads (such as for
hospital administrators or supplies managers) would be
incurred and excluded these from consideration.
Data on resource requirements were collected at four of
the six active VIA screening facilities in Ghana – three in
the Kumasi area (Komfo Anokye Teaching Hospital,
Kumasi South Hospital and Sepe Dote clinic), and one in
Accra (Ridge Hospital). Providers were observed during
performance of their regular activities for between one and
3 days per facility. Providers generally followed the VIA
and cryotherapy protocol that had been established during
the initial set-up of the VIA pilot-study in Ghana (Blu-
menthal et al. 2007; JHPIEGO 2008). However, while the
initial protocol had envisaged VIA screening and treatment
with cryotherapy only for women aged 25–45, providers
had started to screen also older women if the squamocol-
umnar junction was visible.
Information was collected on capital (building, equip-
ment) and recurrent (personnel, supplies) resources used
for VIA and cryotherapy. For VIA, resource use was
collected only for activities directly related to the perfor-
mance of VIA, i.e. we did not include resources used for
evaluation of women referred to physicians for apparent
cancer during visual inspection. For cryotherapy, the entire
treatment process was included, i.e. extra counselling after
a positive VIA test, treatment with cryotherapy, post-
treatment counselling and one follow-up visit after
2 weeks.
To estimate unit costs of labour, staff were asked to
estimate the percentage of effective working time, which
was defined as the time during which they were seeing
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patients, and the percentage of daily working time dedi-
cated to cervical cancer-related activities. Further infor-
mation was obtained from actors involved in developing
the VIA pilot sites and in attempts to scale-up VIA in rural
areas. Resource requirements for mobilization ⁄ recruitment
of women were estimated on the basis of information on
mobilization ⁄ recruitment activities at Kumasi South hos-
pital. Costs attributable to maintenance and utilities were
calculated based on results of a prior costing study from
Ghana (GHS 2000).
Unit costs were collated from multiple sources including
the Kumasi University of Science and Technology
Table 1 Input parameters for modelling of VIA ⁄ cryotherapy costs per woman in Ghana
Basic assumptions High cost Base case Low cost
Capital – buildings
Size 16 m2
Costs per m2 (US$) 2699 1350 1113
Percentage of effective working time 40% 60% 80%
Capital – equipment
General equipment International
equipment
Locally
manufactured
equipment
Cryotherapy-specific equipment
working-life of Cryogun (years)*
1 2 3
Number of patients per year 5.1 45 60
Capital – discount rate 5% 3% 0%
Time requirements
VIA (min) 45 17 15
Cryotherapy (min)§ 60 50 45
Recurrent – staff
Doctor salary (US$) 1620 1350 1012
Nurse salary (US$) 750 389 236
Assistant salary (US$) 81
Number of VIA per nurse per year 1000 600 200
% effective working time– 40% 60% 80%
Supervision (for 4 nurses) 4 doctor h ⁄month + 1 doctor week per year
Recurrent supplies
VIA cryotherapy With gas for boiling of
instruments
Without gas
for boiling of
instruments
Recurrent – mobilisation ⁄ recruitment
(Church group visits (5 nurse h ⁄month + 3.37 US$ transport), central market broadcasts, FM station broadcasts)
Costs per mobilised woman (US$) 1.50
Capital – training course and initial supervision
Trainees 2 doctors, 4 nurses
Facilitators 2 doctors, 2 nurses
Duration 2 weeks
Travel allowance (for trainers) 33.75
Per diem (trainers) (US$) 33.75
Per diem (trainees) (US$) 5
Supervision Year 1 2 doctor h ⁄ day
Supervision Year 2 4 doctor h ⁄week
Time before retraining** 5 years
*At Ridge hospital, cryo guns were replaced every year. At Kumasi South hospital: every other year.
Ridge hospital performed 45 procedures in 2008. Based on an observed VIA positivity rate of 2.53%, assuming 200 screens at low case
load facilities would yield about 5.1 positive screens per year.
At Kumasi South hospital: 17 min. At Sepe Dote: 45 min. In Goldie et al. (2001): 15 min.
§At Kumasi South hospital: 45 min. At Ridge hospital: 60 min.
–Estimated effective working time at Kumasi South and Komfo Anokye hospital: 60%.
**Same as in Legood et al. (2005) and supported by Ghana findings.
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development office for building construction costs, pro-
vider salary slips for personnel costs and market prices for
equipment and supplies (a list of unit costs and prices can
be obtained from the authors). For personnel, unit costs
were calculated by dividing monthly salaries by the
estimated effective working time per month. If necessary,
costs were adjusted to the year 2009 using the country-
specific GDP deflator from IMF (2009) (IMF 2009b).
Calculation of annual economic costs of capital items
followed recommendations by Tan-Torres Edejer et al.
(2003) and used a discount rate of 3%. Costs were
converted to US$, using the average exchange rate for July
2009 (1 GHS = 0.67 US$). Incremental costs per woman
were calculated by multiplying observed resources used
per woman with estimated unit costs (see Appendix S1
for further details on data collection and estimation of
costs).
Modelling of costs per woman
A model was constructed to test the influence of observed
differences between surveyed facilities and providers on
estimated costs. The costing model made assumptions for
costs of inputs, number of women screened and treated per
provider, effective working time of capital and staff, costs
of training and duration of screening ⁄management per
woman (Table 1). The model calculated costs for a ‘Base
Case Scenario’ using assumed resources used per woman
multiplied by their estimated unit costs and tested the
influence of alternative assumptions for input parameters
through sensitivity analyses (SA).
Base Case assumptions usually reflect findings from
observed facilities and considerations about the availability
of infrastructure in the country (MOH 2007). High-Cost
assumptions are based on observed less efficient providers
and building costs at higher quality hospitals. Low-Cost
assumptions assume higher efficiency and numbers of
screened women, low costs of infrastructure and screening
personnel of lower salary categories.
Univariate and multivariate SA were carried out using
the alternative ‘High-Cost’ and ‘Low-Cost’ assumptions.
For the univariate sensitivity analysis, one model param-
eter was varied at a time with all other parameters kept
constant. For the multivariate SA, all variables were
simultaneously set to the ‘Low-Cost’ assumptions or ‘High-
Cost’ assumptions, respectively, to generate the largest
possible range of costs in an analysis of extremes (Briggs
et al. 1994).
Modelling costs of a national VIA ⁄ cryotherapy programme
Costs for scale-up to a national screening programme
(training of providers, purchasing of cryotherapy equip-
ment, etc.) were estimated using ‘Base Case’ model
parameters (Table 1), and assuming a linear relationship
between programme inputs and outputs. (Estimated
resource requirements for scale-up are presented in natural
units in Table S1.) The necessary increase in facility
capacity (buildings and equipment) was calculated from
the assumed time requirements for VIA and cryotherapy
and the number of procedures performed under Base Case
assumptions. This yielded an estimated 19% of building
Table 2 Estimated number of women in
Ghana requiring VIA ⁄ cryotherapy in the
year 2009
Screening strategy
Screen every
five years.
Women 25–45
years*
Screen once
per lifetime
women 35–45
years
VIA 100% coverage 580 406 116 206
VIA 70% coverage 406 284 81 344
Cryotherapy 100% coverage (2.53% of screened)§ 15 265 3056
Cryotherapy 70% coverage (2.53% of screened) 10 685 2139
Cryotherapy 100% coverage (10% of screened)– 58 041 11 621
Cryotherapy 70% coverage (10% of screened) 40 628 8134
*Current practice in Ghana.
WHO (2002) recommendation for low-income countries introducing cervical cancer
screening.
Based on reported female population by age group in WHO ⁄ ICO (2007), extrapolated to
the year 2009 assuming an average population growth rate of 2.0% (WHO 2006).
§2.53%was the proportion of VIA positive women out of all screens between Jan 2008 and
July 2009.
–According to Sankaranarayanan & Wesley (2003), skilled providers identify 8–15% of
screened women as positive. In Blumenthal et al. (2007) test-positivity rate was 13.2%; in
Legood et al. (2005): 10%.
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space (one room of 16 m square, 60% effective working
time) being used for VIA ⁄ cryotherapy for every screening
nurse employed.
As scale-up costs were estimated separately, national
annual VIA ⁄ cryotherapy programme costs were calcu-
lated for two different scenarios: one scenario excluded
start-up costs (training, buildings and equipment); the
other scenario included annuitized start-up costs. To do
so, modelled incremental economic costs per woman
under Base Case assumptions (with ⁄without cost catego-
ries of training, buildings, equipment) were multiplied
with assumed numbers of women requiring screening in
the year 2009 in Ghana. Table 2 presents estimated
numbers of women requiring screening under different
combinations of assumptions for screening strategy and
coverage.
Results
Costs at surveyed facilities
Figure 1 presents estimated incremental economic costs per
woman screened with VIA. Only three of the four visited
facilities had VIA cases on survey days. Estimated costs
show large variations, ranging from 4.93 US$ (7.30 GHS)
to 14.75 US$ (21.86 GHS). Personnel accounted for the
largest share of incremental costs at all facilities (between
45% and 61%), while capital costs ranged from 16% to
45%. Costs for mobilization ⁄ recruitment per woman were
estimated at 1.50 US$ (2.22 GHS), but are included only in
reported results for Kumasi South hospital.
Incremental economic costs per woman treated with
cryotherapy are presented in Figure 2. Only two facilities
had functioning cryotherapy equipment, while the two
others were referring women to another hospital for
treatment. Reported costs include extra counselling after
a positive VIA test, treatment with cryotherapy,
post-treatment counselling and one follow-up visit after
2 weeks. The costs per woman treated with cryotherapy in
addition to those for VIA varied between 47.26 US$ (70.04
GHS) and 84.48 US$ (125.19 GHS). The cryotherapy
equipment accounted for the largest share of costs at both
hospitals, comprising 66–77% of total costs.
Modelled costs per woman
Figure 3 presents the estimated incremental economic costs
per woman screened with VIA. Under base case assump-
tions for input parameters, VIA costs per woman were
estimated at 6.12 US$ (9.07 GHS). Personnel,
mobilization ⁄ recruitment of women and training of pro-
viders were estimated to be the three most important cost
categories accounting for 27%, 24% and 23%, respec-
tively. Univariate SA showed that the staff time per VIA
screen and the number of women screened per provider
have the largest influence on estimated costs per woman.
Multivariate SA, simultaneously setting all model input
parameters to High-Cost and Low-Cost assumptions,
respectively, demonstrated the high impact which alterna-
tive assumptions have on estimated costs per woman
(lowest bar in Figure 3): the High-Cost Scenario (worst
case) estimates are more than four times the size of costs
estimated for the Base Case Scenario.
Figure 4 presents results of modelling the incremental
economic costs of cryotherapy under varying assumptions.
Under Base Case assumptions for input parameters, incre-
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Figure 1 Costs of visual inspection with acetic acid at surveyed
facilities: Incremental economic costs per woman (2009 USD).
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Figure 2 Costs of cryotherapy at surveyed facilities: Incremental
economic costs per woman (2009 USD).
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mental economic costs of cryotherapy were estimated at
27.96 US$ (41.43 GHS) per woman treated. Cryotherapy
equipment was estimated to account for 62% of total
costs. Univariate SA found the number of treated patients
per facility per year to be the main determinant of costs of
cryotherapy per patient. Multivariate SA showed that costs
can increase more than ten times from the Base Case
Scenario to about 338 US$ (500 GHS), if all model
parameters are set to the alternative High-Cost assump-
tions.
National VIA ⁄ cryotherapy costs
Table 3 presents estimated VIA ⁄ cryotherapy costs for
scale-up (investment costs) and annual costs for running a
national programme in Ghana. Results are shown
separately for different scenarios of coverage and screen-
ing strategy and, for annual costs, excluding and includ-
ing annuitized start-up costs. Depending on the screening
strategy and assumed coverage, scale-up (investment)
costs were estimated to be between 0.8 and 5.7 million
25.26
9.92
9.33
7.52
6.98
6.42
6.61
6.32
6.12
6.15
3.95
5.85
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Time per VIA screen (min) (15 – 45)
Number of VIA screens/nurse/year (1000 – 200)
Provider salary (236 US$ – 750 US$)
Personnel: % effective working time (80% – 40%)
Capital: % effective working time (80% – 40%)
Building costs per sqm (1113 US$ – 2699 US$)
Discount rate (0% – 5%)
Type of equipment (local – international equipment)
Nurse trainer salary (390 US$ – 750 US$)
Incremental economic costs per woman screened with VIA (2009 US$)
Base case
6.12 US$ Parameters (low – high value for sensitivity analysis)
Figure 3 Modelled incremental economic costs per woman screened with inspection with acetic acid and results of sensitivity analysis
(SA): Effects of variation of model input parameters on estimated costs.
337.68
172.74
44.71
31.84
30.48
29.39
28.80
29.31
28.83
27.96
14.57
23.38
22.02
26.32
26.70
27.71
26.76
27.28
27.53
27.77
0 US$ 50 US$ 100 US$ 150 US$ 200 US$ 250 US$ 300 US$ 350 US$ 400 US$
Best Case - Worst Case (all values at minimum – maximum)
Number of patients treated/facility (60 – 5.1)
Working-life of cryotherapy equipment (years) (3 – 1) 
Provider salary (236 US$ – 750 US$)
Personnel: % effective working time (80% – 40%)
Costs per sqm (1113 US$ – 2699 US$)
Discount rate (0% – 5%)
Cryotherapy duration (min) (45 – 60)
Capital: % effective working time (80% – 40%)
Facility equipment (local – international)
Incremental economic cost per cryotherapy (2009 US$)
Base case
27.96 US$ Parameters (low – high value for sensitivity analysis)
Figure 4 Modelled incremental economic costs per woman treated with cryotherapy and results of sensitivity analysis (SA): Effects of
variation of model input parameters on estimated costs.
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US$ (1.2 and 8.5 million GHS). Accordingly, annual costs
for running a national programme (including annuitized
costs of capital) were estimated to be between 0.6 and 4.0
million US$ (0.8 and 5.9 million GHS), when assuming a
VIA positivity rate of 2.53% as is currently the case in
Ghana. Under the assumption of a VIA positivity rate
of 10% as reported in the international literature
(Sankaranarayanan & Wesley 2003; Legood et al. 2005;
Blumenthal et al. 2007), total costs of the national
programme would increase to between 0.7 and 5.2
million US$ (1.1 and 7.7 million GHS) with the
proportion of cryotherapy costs rising from 11% (if VIA
positivity were 2.53%) to 31% of total screening
programme costs.
Discussion
A single-visit approach consisting of VIA followed by
immediate cryotherapy for all eligible women remains one
of the internationally recommended screening strategies for
developing countries (FIGO 2009). Our study is the first to
report detailed resource-use-based cost estimates for VIA
and cryotherapy in an African setting, which are essential
for planning of resource allocation and for future cost-
effectiveness analyses evaluating VIA against alternative
prevention strategies. In addition, we estimated resource
requirements for a national cervical cancer screening
programme in Ghana.
Results from surveyed facilities showed high variability
of VIA and cryotherapy costs in Ghana. VIA costs lie
closer to figures previously published for South Africa
(10.63 US$) than to those estimated for Kenya (1.31
US$) (Goldie et al. 2005) and were also above costs
reported for Thailand (1.14 US$) and India (4.68 U$)
(Mandelblatt et al. 2002; Legood et al. 2005).1
Modelling of costs per woman found volume effects
such as numbers of women screened per nurse or treated
per cryotherapy machine to be important determinants.
The estimation of national VIA ⁄ cryotherapy costs, if such
a programme had been in place in Ghana in 2009
showed that under Base Case cost assumptions, total
costs of the programme would have remained at <1% of
total health expenditures for all combinations of screen-
ing strategy and coverage [based on data from 2008
(MOH 2009)].
According to estimates by Goldie et al. (2005) for five
developing countries, a fully functioning VIA ⁄ cryotherapy
programme could reduce women’s lifetime risk of cervical
cancer by about 50% (assuming sensitivity of VIA of 76%,
and a screening strategy with three tests at age 35, 40 and
45 years). However, the effectiveness of VIA has recently
come under debate, as most evaluations of the performance
of VIA may have overestimated its sensitivity by up to 20%
Table 3 Estimated costs for a national VIA ⁄ cryotherapy programme: national scale-up and annual programme costs for the year 2009
Screening strategy
Every five years Once a lifetime
100% coverage 70% coverage 100% coverage 70% coverage
Start-up costs for national VIA ⁄ cryotherapy programme (US$)
Training costs 799 844 559 891 160 141 112 098
Cryotherapy equipment 489 475 342 633 98 000 68 600
Increasing facility capacity 4 444 173 3 110 921 889 789 622 853
Total 5 733 492 4 013 444 1 147 930 803 551
Annual running costs for national VIA ⁄ cryotherapy programme (US$)
VIA 2 367 793 1 657 455 474 067 331 847
Cryotherapy (2.53% of screened) 130 524 91 367 26 133 18 293
Cryotherapy (10% of screened) 515 904 361 133 103 292 72 304
Total (low number of cryotherapy) 2 498 317 1 748 822 500 200 350 140
Total (high number of cryotherapy) 2 883 698 2 018 588 577 359 404 151
Annual costs including annuitized start-up costs (US$)
VIA 3 554 108 2 487 876 711 585 498 110
Cryotherapy (2.53% of screened) 410 594 287 416 82 207 57 545
Cryotherapy (10% of screened) 1 622 901 1 136 031 324 929 227 450
Total (low number of cryotherapy) 3 964 702 2 775 291 793 792 555 655
Total (high number of cryotherapy) 5 177 009 3 623 906 1 036 514 725 560
1Published results were converted to year 2009 US$ using (IMF
2009a) GDP deflators and PPP conversion rates.
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because of use of an inappropriate gold standard
(i.e. colposcopy directed biopsy) (Pretorius et al. 2007;
Cagle et al. 2010). Consequently, results of previous
cost-effectiveness analyses need to be interpreted with
caution, as they assume relatively high sensitivity rates
for VIA. In addition, a large-scale 8-year screening trial
from India found reductions in advanced cervical cancer
incidence and mortality only for women screened with
HPV DNA tests and not with VIA or cytology (Sankar-
anarayanan et al. 2009). As more affordable and rapid
HPV DNA detection tests (e.g. CareHPV) are becoming
available, cost-effectiveness of VIA compared with new
HPV tests will need to be reevaluated.
When interpreting our findings, important data and
methodological limitations need to be considered. First,
some data were not available during our observations
of providers’ activities, which make the information
less reliable: the percentage of effective working
time, resources used for training or for recruitment ⁄
mobilization of women and the life-expectancy of cryo-
therapy equipment had to be estimated based on provider
accounts. In addition, providers were unable to relate life-
expectancy of cryotherapy equipment to the volume of
treated patients. Therefore, our analysis assumed that life-
expectancy was not significantly dependent upon the
number of patients treated per year. Furthermore, this
study was unable to relate costs to relevant outcomes for
cervical cancer prevention, as no information was available
on the effectiveness of providers in Ghana to detect and
treat precancerous lesions. While evaluations comparing
providers’ performance quality with that of a ‘Master
Trainer’ have confirmed quality was maintained beyond
the pilot project (JHPIEGO 2008; Sanghvi et al. 2008),
VIA positivity rates have dropped from 13% during the
time of the pilot project (Blumenthal et al. 2007), when
quality assurance and regular supervision were still avail-
able, to about 2.5% in recent years.
Second, our methodological approach to estimating
incremental costs through an ingredients approach may
have inherent shortcomings: (i) systems costs (such as
administrative and overhead costs) were excluded. Yet,
these cost categories are important because insufficient
support and attention to management can contribute to
programmes failing during implementation; (ii) the ingre-
dients approach may underestimate wastage and losses,
which would have been accounted for by using a step down
methodology based on total hospital usage (though satis-
factory allocation factors for attributing costs of supplies to
such a small add-on project remains challenging). Both
types of limitations may have led to under-estimation of
resource requirements to implement a national cervical
cancer screening programme. Furthermore, a national
screening programme would result in additional costs for
the treatment of detected cervical cancer patients, and for
(re)screening of women for whom VIA could not be
completed (e.g. if the squamocolumnar junction could not
be visualized).
Third, model assumptions are always open to criticism.
Our model calculated national programme costs based on
assumptions derived from observations at only three
screening facilities in the country. In addition, it assumed
that mobilization ⁄ recruitment costs remained constant for
every woman recruited for screening. Yet, it is likely that
the costs per woman depend on specific characteristics of
the screening programme, such as geographic accessibility
of facilities and the duration of the programme. Another
limitation is that we calculated national scale-up and
annual programme costs under the assumption of constant
returns to scale. However, our results suggest the presence
of economies of scale in conducting VIA and cryotherapy,
which would imply lower average costs per woman
screened when screening higher numbers of women. Yet,
our sample was too small to identify optimal scale of
operation. Furthermore, results would have been different,
if alternative High-Cost or Low-Cost estimates would have
been considered for calculating annual programme costs.
Despite these caveats, our research has major implica-
tions for programme managers and researchers. First, costs
of VIA and cryotherapy are highly context-dependent, even
within the public sector of one country, showing large
variability between facilities. Second, volume effects are an
important determinant of costs per woman screened and
treated with cryotherapy.
Economies of scale have not been considered in prior
cost-effectiveness studies of cervical cancer prevention
strategies in developing countries (Goldie et al. 2001,
2005; Mandelblatt et al. 2002) and are rarely discussed in
cost-effectiveness analyses in general (Elbasha & Messon-
nier 2004). Yet, economies of scale have been found to
exist in HIV prevention programmes (Dandona et al. 2008;
Chandrashekar et al. 2010) and are likely to be important
for cost-effectiveness analyses informing decisions on
different cervical cancer prevention strategies. For exam-
ple, in a context where low uptake of screening is an
impediment to scaling-up, recommendations to screen only
once instead of twice or more times per lifetime are likely
to result in fewer screenings and, consequently, higher
costs per screen. Therefore, international recommendations
(WHO 2002; Sherris et al. 2009), which were supported by
prior cost-effectiveness studies suggesting that screening
only once per lifetime is the most cost-effective screening
strategy (Goldie et al. 2005), may need to be reconsidered.
As scale is an important determinant of costs, policy-
makers in Ghana and elsewhere should aim to increase the
Tropical Medicine and International Health volume 16 no 3 pp 379–389 march 2011
W. Quentin et al. Costs of cervical cancer screening in Ghana
386 ª 2011 Blackwell Publishing Ltd
number of women screened per facility. To do so, demand-
side barriers such as user-fees, which were introduced at
Ghanaian screening facilities after discontinuation of
external support, should be removed and replaced by
continued public funding. Availability of services needs to
be assured as non-functional cryotherapy machines are
discouraging both, providers and clients. Investing in
recruitment ⁄mobilization campaigns becomes important to
make efficient use of resources. Approaches to integrate
screening in family planning clinics appear useful, as they
allow easy recruitment of women attending such services,
and at the same time, women receiving screening can
benefit from treatment of vaginal infections detected
during visual inspection.
Policy-makers should be aware that trade-offs may exist:
improving geographic accessibility is likely to result in
higher costs of screening and treatment per woman.
However, concentrating screening at urban centres could
exacerbate inequalities between urban and rural popula-
tions. Planning for scale-up of cervical cancer screening
becomes more difficult when having to consider economies
of scale because assuming a simple linear relationship
between inputs (employed resources) and outputs (number
of women screened ⁄ treated) appears to be inadequate.
When choosing between different cervical cancer preven-
tion strategies, including vaccination, low-cost HPV tests
and VIA ⁄ cryotherapy alone or in combination, the feasi-
bility of increasing uptake of screening to achieve econo-
mies of scale should be a major concern.
In conclusion, scaling-up screening in developing coun-
tries remains essential to achieve reductions in female
cancer mortality. In doing so, policy-makers should pay
particular attention to the most important determinants of
costs of VIA and cryotherapy identified in our study.
Research should focus more attention on the determinants
of costs and consider that economies of scale are likely to
exist when embarking on necessary future cost-effective-
ness analyses of alternative cervical cancer prevention
strategies.
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